Editor’s Choice: Lunchbox Trial Listen to Gynecologic Oncology
-
- Science
Editor’s Choice Paper:
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma
Editorial:
What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical College
Gretchen Glaser, MD, Mayo Clinic
John Weroha, MD, Mayo Clinic
Editor’s Choice Paper:
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma
Editorial:
What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer
Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology
Featuring:
Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical College
Gretchen Glaser, MD, Mayo Clinic
John Weroha, MD, Mayo Clinic
10 min